To a blurry eye, Bausch Lomb's beaten-up share price might look like a buying opportunity. If your vision is clear, it's not.
The stock (symbol BOL) has plummeted 20% since Monday, when the company said it would temporarily stop shipments of its ReNu with MoistureLoc contact lens solution. The reason: fear that the product might be connected with a rare fungal eye infection. The stock market could be overreacting. It did, after all, do just that to Sherwin-Williams in February after a jury found the company liable in a lead-paint case. That stock lost one-fifth of its value in a single day. But it has recovered almost fully as the market reassessed the implications to Sherwin-Williams' businesses and found them less than dire.
However, with Bausch Lomb, savvy investors would be wise to hold off rather than expect a quick bounceback, analysts say. Although there's no evidence that the infections are caused by the firm's product, the uncertainty is great and the full implications unknown.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The Centers for Disease Control and Prevention is investigating several reports of Fusarium keratitis infections. The cause of the infections has yet to be determined, "although evidence thus far remains concerning" for BL, says Suey Wong, an analyst at Robert W. Baird Co. Nearly all of the infected patients so far reviewed by the CDC have said they used ReNu products. How long the investigation will take isn't clear. But in the meantime, the brand name is tainted. Major retail chains are pulling ReNu products from their shelves.
This is a big deal for BL. It generates 23% of its sales from lens-care products, sold under the Bausch Lomb, Boston, ReNu and Sensitive Eyes names. It launched ReNu with MoistureLoc in 2004. Bank of America analyst David Maris says that brand isn't likely to return to the U.S. market, resulting in the loss of $45 million in potential sales this year. He figures BL will lose share of the overall lens care market and that its contact lens sales could be hurt as well. "We think the brand damage on ReNu will be sizable and carry over into the Bausch Lomb overall brand globally," he says. On Wednesday, Maris lowered his 2006 earnings per share estimate from $4.24 to $3.05. He also lowered his 12-month target price for the stock from $49 to $40 and maintains a "sell" rating.
Maris also wonders what the company will say to some questions about its handling of the situation, including why doctors weren't notified sooner and the timeline wasn't explained better to investors. Such worries could add to the long-term problems for the firm, in his view.
BL has more worries than ReNu. Competition among eye-care companies -- including Johnson Johnson, Alcon and others -- is tough. Analysts acknowledge that BL hasn't invested enough in research and development, resulting in a weak product pipeline. Wong, who rates the stock "neutral," points out that a recent accounting scandal at a subsidiary in Brazil caused the company to restate five years of financial results and that accounting at a Korean subsidiary is also under investigation. BL said this week that it would further delay its 10-K filing.
--Lisa Dixon
-
Americans, Even With Higher Incomes, Are Feeling the SqueezeA 50-year mortgage probably isn’t the answer, but there are other ways to alleviate the continuing sting of high prices
-
Hiding the Truth From Your Financial Adviser Can Cost YouHiding assets or debt from a financial adviser damages the relationship as well as your finances. If you're not being fully transparent, it's time to ask why.
-
How to Manage a Disagreement With Your Financial AdviserKnowing how to deal with a disagreement can improve both your finances and your relationship with your planner.
-
If You'd Put $1,000 Into Caterpillar Stock 20 Years Ago, Here's What You'd Have TodayCaterpillar stock has been a remarkably resilient market beater for a very long time.
-
I'm a 55-Year-Old Dad. Here’s How My 28-Year-Old Daughter Showed Me That AXP Is Still a Solid InvestmentAmerican Express stock is still a solid investment because management understands the value of its brand and is building a wide moat around it.
-
If You'd Put $1,000 Into AMD Stock 20 Years Ago, Here's What You'd Have TodayAdvanced Micro Devices stock is soaring thanks to AI, but as a buy-and-hold bet, it's been a market laggard.
-
If You'd Put $1,000 Into UPS Stock 20 Years Ago, Here's What You'd Have TodayUnited Parcel Service stock has been a massive long-term laggard.
-
How the Stock Market Performed in the First Year of Trump's Second TermSix months after President Donald Trump's inauguration, take a look at how the stock market has performed.
-
If You'd Put $1,000 Into Lowe's Stock 20 Years Ago, Here's What You'd Have TodayLowe's stock has delivered disappointing returns recently, but it's been a great holding for truly patient investors.
-
If You'd Put $1,000 Into 3M Stock 20 Years Ago, Here's What You'd Have TodayMMM stock has been a pit of despair for truly long-term shareholders.
-
If You'd Put $1,000 Into Coca-Cola Stock 20 Years Ago, Here's What You'd Have TodayEven with its reliable dividend growth and generous stock buybacks, Coca-Cola has underperformed the broad market in the long term.
